TGFB1 and neoplasm: Exogenous TGF-β1 promoted the processes formation, and Galunisertib reduced the growth of tumor spheres in RR 1306MG 3.5GR6 (119.0 ± 5.1 μm vs. 96.6 ± 2.5 μm, p < 0.001) (Figure 7A) and RTR 1306MG R6T3 (107.8 ± 0.6 μm vs. 93.3 ± 2.3 μm, p < 0.001) (Figure 7B).